



Humira® (adalimumab) – Expanded orphan indication

- On September 28, 2018, the [FDA approved](#) AbbVie's [Humira \(adalimumab\)](#) for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
 - Previously, Humira was approved for use in adults for this indication.
- Humira is also FDA-approved for the following conditions: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
- The safety and efficacy of Humira for the treatment of pediatric uveitis were assessed in a placebo-controlled study of 90 patients from 2 to < 18 years of age with active juvenile idiopathic arthritis-associated non-infectious uveitis. The primary endpoint was time to treatment failure, defined as worsening or sustained non-improvement in ocular inflammation, or worsening of ocular comorbidities.
 - Humira significantly decreased the risk of treatment failure by 75% relative to placebo (hazard ratio = 0.25 [95% CI: 0.12, 0.49]).
- Humira carries a boxed warning for serious infections and malignancy.
- The recommended dose of Humira for patients ≥ 2 years of age with pediatric uveitis is weight-based:
 - 10 kg (22 lbs) to < 15 kg (33 lbs): 10 mg every other week (10 mg prefilled syringe)
 - 15 kg (33 lbs) to < 30 kg (66 lbs): 20 mg every other week (20 mg prefilled syringe)
 - ≥ 30 kg (66 lbs): 40 mg every other week (Humira pen or 40 mg prefilled syringe)
- Refer to the Humira drug label for dosing recommendations for all other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.